PTPhilip N. Tsichlis

Philip N. Tsichlis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip N. Tsichlis has a total of 165 co-authors. Here are the top co-authors by number of shared publications:

  • George Laliotis

    Department of Cancer Biology and Genetics, The Ohio State University, Columbus, USA

    11 shared publications
  • Evangelia Chavdoula

    The Ohio State University

    8 shared publications
  • Filippos Kottakis

    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111

    8 shared publications
  • Lalit Sehgal

    Division of Hematology, College of Medicine, The Ohio State University, Columbus, USA

    8 shared publications
  • Alessandro La Ferlita

    Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States; The Ohio State University, Comprehensive Cancer Center, Columbus, OH, United States

    7 shared publications
  • Christos Polytarchou

    Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111, USA; Division of Digestive Diseases, Center for Systems Biomedicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

    7 shared publications

Latest Publications

  • Open Access

    KDM2B is required for ribosome biogenesis and its depletion unequally affects mRNA translation

    by Vollter Anastas, Evangelia Chavdoula, Alessandro La Ferlita, Burak Soysal, Ilaria Cosentini, Giovanni Nigita, Michael G. Kearse, Philip N. Tsichlis

    KDM2B is a JmjC domain lysine demethylase, which promotes cell immortalization, stem cell self-renewal and tumorigenesis. Here we employed a multi-omics strategy to address its role in ribosome biogenesis and mRNA translation. These processes are required to sustain cell proliferation, an important cancer hallmark. Contrary to earlier observations, KDM2B promotes ribosome biogenesis by stimulating the transcription of genes encoding ribosome biogenesis factors and ribosomal proteins, particularly those involved in the biogenesis of the 40S ribosomal subunits. Knockdown of KDM2B impaired the assembly of the small and large subunit processomes, as evidenced by specific defects in pre-ribosomal RNA processing. The final outcome was a decrease in the rate of ribosome assembly and in the abundance of ribosomes, and inhibition of mRNA translation. The inhibition of translation was distributed unequally among mRNAs with different features, suggesting that mRNA-embedded properties influence how mRNAs interpret ribosome abundance. This study identified a novel mechanism contributing to the regulation of translation and provided evidence for a rich biology elicited by a pathway that depends on KDM2B, and perhaps other regulators of translation.


  • Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4

    by Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar, et al.


  • Open Access

    AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis

    by Siobhan K. McRee, Abraham L. Bayer, Jodie Pietruska, Philip N. Tsichlis, Philip W. Hinds

    Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer, due to its highly metastatic nature. Melanomas harboring oncogenic BRAF V600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT-isoform specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo , while AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that elucidation of AKT2-specific functions in metastasis could inform therapeutic strategies to improve treatment options for melanoma patients. Graphical


  • Retraction
    Open Access

    Retraction Note: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing

    by Georgios I. Laliotis, Evangelia Chavdoula, Maria D. Paraskevopoulou, Abdul Kaba, Alessandro La Ferlita, Satishkumar Singh, Vollter Anastas, Keith A. Nair, Arturo Orlacchio, Vasiliki Taraslia, et al.

  • Open Access

    AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology

    by Apostolia-Maria Tsimberidou, Antonis Skliris, Alan Valentine, Jamie Shaw, Ursula Hering, Henry Hiep Vo, Tung On Chan, Roger S. Armen, Jeffrey R. Cottrell, Jen Q. Pan, et al.

    Background: Changes in the expression and activity of the AKT oncogene play an important role in psychiatric disease. We present translational data assessing the role of AKT in psychiatric symptoms. Methods: (1) We assessed the protein activity of an AKT3 mutant harboring a PH domain mutation (Q60H) detected in a patient with schizophrenia, the corresponding AKT1 mutant (Q61H), and wild-type AKT1 and AKT3 transduced in AKT-null mouse fibroblasts and modeled the Q61H mutation onto the crystal structure of the Akt1 PH domain. (2) We analyzed the results of earlier genome-wide association studies to determine the distribution of schizophrenia-associated single-nucleotide polymorphisms (SNPs) in the AKT3 gene. (3) We analyzed the psychiatric adverse events (AEs) of patients treated with M2698 (p70S6K/AKT1/AKT3 inhibitor) and with other PI3K/AKT/mTOR pathway inhibitors. Results: (1) Proteins encoded by AKT3 (AKT3Q60H) and AKT1 (AKT1Q61H) mutants had lower kinase activity than those encoded by wild-type AKT3 and AKT1, respectively. Molecular modeling of the AKT1-Q61H mutant suggested conformational changes that may reduce the binding of D3-phosphorylated phosphoinositides to the PH domain. (2) We identified multiple SNPs in the AKT3 gene that were strongly associated with schizophrenia (p < 0.5 × 10–8). (3) Psychiatric AEs, mostly insomnia, anxiety, and depression, were noted in 29% of patients treated with M2698. In randomized studies, their incidence was higher in PI3K/AKT/mTOR inhibitor arms compared with placebo arms. All psychiatric AEs were reversible. Conclusions: Our data elucidate the incidence and mechanisms of psychiatric AEs in patients treated with PI3K/AKT/mTOR inhibitors and emphasize the need for careful monitoring.


  • Retraction
    Open Access

    Retraction Note: Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection

    by Georgios I. Laliotis, Adam D. Kenney, Evangelia Chavdoula, Arturo Orlacchio, Abdul Kaba, Alessandro La Ferlita, Vollter Anastas, Christos Tsatsanis, Joal D. Beane, Lalit Sehgal, et al.

  • Open Access

    PRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and Ca2+/NFAT Signaling

    by Shouvonik Sengupta, Kelsi O West, Shridhar Sanghvi, Georgios Laliotis, Laura M. Agosto, Kristen W. Lynch, Philip N. Tsichlis, Harpreet Singh, Kristin L. Patrick, Mireia Guerau-De-Arellano

    Protein arginine methyltransferase (PRMT) 5 is the type 2 methyltransferase catalyzing symmetric dimethylation of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TCR engagement-induced IL-2 production and Th cell expansion and confers protection against experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis. However, the mechanisms by which PRMT5 modulates Th cell proliferation are still not completely understood, and neither are the methylation targets in T cells. In this manuscript, we uncover the role of PRMT5 on alternative splicing in activated mouse T cells and identify several targets of PRMT5 symmetric dimethylation involved in splicing. In addition, we find a possible link between PRMT5-mediated alternative splicing of transient receptor potential cation channel subfamily M member 4 (Trpm4) and TCR/NFAT signaling/IL-2 production. This understanding may guide development of drugs targeting these processes to benefit patients with T cell–mediated diseases.


  • Retracted
    Open Access

    RETRACTED ARTICLE: Phosphor-IWS1-dependent U2AF2 splicing regulates trafficking of CAR-E-positive intronless gene mRNAs and sensitivity to viral infection

    by Georgios I. Laliotis, Adam D. Kenney, Evangelia Chavdoula, Arturo Orlacchio, Abdul Kaba, Alessandro La Ferlita, Vollter Anastas, Christos Tsatsanis, Joal D. Beane, Lalit Sehgal, et al.

    AKT-phosphorylated IWS1 promotes Histone H3K36 trimethylation and alternative RNA splicing of target genes, including the U2AF65 splicing factor-encoding U2AF2. The predominant U2AF2 transcript, upon IWS1 phosphorylation block, lacks the RS-domain-encoding exon 2, and encodes a protein which fails to bind Prp19. Here we show that although both U2AF65 isoforms bind intronless mRNAs containing cytoplasmic accumulation region elements (CAR-E), only the RS domain-containing U2AF65 recruits Prp19 and promotes their nuclear export. The loading of U2AF65 to CAR-Elements was RS domain-independent, but RNA PolII-dependent. Virus- or poly(I:C)-induced type I IFNs are encoded by genes targeted by the pathway. IWS1 phosphorylation-deficient cells therefore, express reduced levels of IFNα1/IFNβ1 proteins, and exhibit enhanced sensitivity to infection by multiple cytolytic viruses. Enhanced sensitivity of IWS1-deficient cells to Vesicular Stomatitis Virus and Reovirus resulted in enhanced apoptotic cell death via caspase activation. Inhibition of this pathway may therefore sensitize cancer cells to oncolytic viruses.


  • Retracted
    Open Access

    Overexpression of the SETD2 WW domain inhibits the phosphor-IWS1/SETD2 interaction and the oncogenic AKT/IWS1 RNA splicing program

    by Georgios I. Laliotis, Evangelia Chavdoula, Vollter Anastas, Satishkumar Singh, Adam D. Kenney, Samir Acharya, Jacob S. Yount, Lalit Sehgal, Philip N. Tsichlis

    Our earlier studies had shown that AKT phosphorylates IWS1, and that following phosphorylation, IWS1 recruits the histone methyltransferase SETD2 to an SPT6/IWS1/ALY complex, which assembles on the Ser2-phosphorylated CTD of RNA Pol II. Recruited SETD2 methylates histone H3 at K36, during transcriptional elongation of target genes, and this regulates multiple steps in RNA metabolism. By regulating the RNA splicing of U2AF2, it controls cell proliferation. Importantly, pathway activity correlates with grade, stage and metastatic potential of lung adenocarcinomas, especially those with EGFR mutations. By regulating nucleocytoplasmic mRNA transport of intronless genes, including those encoding type I IFNs, it regulates sensitivity to viral infection. Here, we show that SETD2 interacts with IWS1 via its WW domain, that the interaction is IWS1 phosphorylation-dependent and that WW domain overexpression blocks the interaction and inhibits the pathway and its biological outcomes. We conclude that blocking the phosphor-IWS1/SETD2 interaction is feasible and has significant therapeutic potential in human cancer.

  • Retracted
    Open Access

    RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing

    by Georgios I. Laliotis, Evangelia Chavdoula, Maria D. Paraskevopoulou, Abdul Kaba, Alessandro La Ferlita, Satishkumar Singh, Vollter Anastas, Keith A. Nair, Arturo Orlacchio, Vasiliki Taraslia, et al.

    AKT-phosphorylated IWS1 regulates alternative RNA splicing via a pathway that is active in lung cancer. RNA-seq studies in lung adenocarcinoma cells lacking phosphorylated IWS1, identified a exon 2-deficientU2AF2splice variant. Here, we show that exon 2 inclusion in theU2AF2mRNA is a cell cycle-dependent process that is regulated by LEDGF/SRSF1 splicing complexes, whose assembly is controlled by the IWS1 phosphorylation-dependent deposition of histone H3K36me3 marks in the body of target genes. The exon 2-deficientU2AF2mRNA encodes a Serine-Arginine-Rich (RS) domain-deficient U2AF65, which is defective inCDCA5pre-mRNA processing. This results in downregulation of theCDCA5-encoded protein Sororin, a phosphorylation target and regulator of ERK, G2/M arrest and impaired cell proliferation and tumor growth. Analysis of human lung adenocarcinomas, confirmed activation of the pathway inEGFR-mutant tumors and showed that pathway activity correlates with tumor stage, histologic grade, metastasis, relapse after treatment, and poor prognosis.